Connor, Clark & Lunn Investment Management (CC&L)’s Oramed Pharmaceuticals ORMP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121K	Sell	25,207 -25,000	-50%	-$99.5K	﹤0.01%	1590
2026 Q1	$171K	Buy	50,207 +6,472	+15%	+$22K	﹤0.01%	1488
2025 Q4	$125K	Buy	43,735 +15,492	+55%	+$40K	﹤0.01%	1473
2025 Q3	$74.6K	Sell	28,243 -32,206	-53%	-$71.2K	﹤0.01%	1463
2025 Q2	$136K	Sell	60,449 -26,687	-31%	-$58.9K	﹤0.01%	1442
2025 Q1	$186K	Sell	87,136 -19,926	-19%	-$46K	﹤0.01%	1334
2024 Q4	$259K	Sell	107,062 -4,457	-4%	-$10.6K	﹤0.01%	1281
2024 Q3	$272K	Buy	+111,519	New	+$272K	﹤0.01%	1269
2022 Q1	–	Sell	-50,786	Closed	-$725K	–	1164
2021 Q4	$725K	Buy	50,786 +24,932	+96%	+$521K	﹤0.01%	727
2021 Q3	$568K	Buy	+25,854	New	+$440K	﹤0.01%	746

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ORMP Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Oramed Pharmaceuticals (ORMP) stake by 50% in Q2 2026, selling an estimated $99.5K and leaving 25,207 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ORMP in Q3 2021 and has held it in 10 quarters since. The position peaked at $725K in Q4 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 25,207 shares of Oramed Pharmaceuticals worth $121K as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 25,000 Oramed Pharmaceuticals shares in Q2 2026, an estimated $99.5K.
Oramed Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1590 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Oramed Pharmaceuticals in Q3 2021 and has held it in 10 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Oramed Pharmaceuticals position peaked at $725K in Q4 2021.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.